Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Phase 3 LATIFY Study - Ceralasertib + Durvalumab vs. Docetaxel in Patients With Locally Advanced or Metastatic NSCLC That Progressed on or After Anti-PD-(L)1 & Platinum-Based Therapy"

135 views
July 9, 2023
Comments 0
Login to view comments. Click here to Login